Research programme : G protein-coupled receptor 75 antagonist - Confo Therapeutics
Latest Information Update: 07 Feb 2025
At a glance
- Originator Confo Therapeutics
- Class Obesity therapies
- Mechanism of Action G protein-coupled receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Obesity
Most Recent Events
- 31 Jul 2024 Confo Therapeutics has patent protection for Confo® technology platform in more than 10 patent families worldwide, prior to July 2024 (Confo Therapeutics website, July 2024)
- 26 Jul 2024 Early research in Obesity in Belgium (unspecified route), prior to July 2024
- 15 Dec 2021 Confo Therapeutics has patent protection for methods for screening GPCRs using ConfoBodies®, GPCR-ConfoBody® complexes, developments of the ConfoBody® platform in ConfoScreen®, ConfoSensor®, ConfoChimer™ and ConfoStructure™ technologies in USA and European Union